{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:02:16Z","timestamp":1790182936518,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.bcp.2011.07.073","type":"journal-article","created":{"date-parts":[[2011,7,24]],"date-time":"2011-07-24T11:47:22Z","timestamp":1311508042000},"page":"1467-1477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1\/2 as antitumor targets"],"prefix":"10.1016","volume":"82","author":[{"given":"Federica","family":"Barbieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"W\u00fcrth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto E.","family":"Favoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pattarozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ratto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Bajetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullio","family":"Florio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2011.07.073_bib0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma epidemiology, carcinogenesis, and pathogenesis","volume":"9","author":"Yang","year":"2008","journal-title":"Current Treatment Options in Oncology"},{"key":"10.1016\/j.bcp.2011.07.073_bib0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/annonc\/mdi094","article-title":"Chemotherapy options and new advances in malignant pleural mesothelioma","volume":"16","author":"Steele","year":"2005","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.bcp.2011.07.073_bib0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2011.03.011","article-title":"Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma","author":"Favoni","year":"2011","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.bcp.2011.07.073_bib0020","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1378\/chest.08-2665","article-title":"Malignant pleural mesothelioma: an update on biomarkers and treatment","volume":"136","author":"Ray","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.bcp.2011.07.073_bib0025","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bcp.2011.07.073_bib0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2011.07.073_bib0035","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/thx.2006.069872","article-title":"Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed","volume":"62","author":"Bertino","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.bcp.2011.07.073_bib0040","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-07-1388","article-title":"Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts","volume":"14","author":"Bertino","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bcp.2011.07.073_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2011.01.001","article-title":"Advances in the biology of malignant pleural mesothelioma","author":"Zucali","year":"2011","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.bcp.2011.07.073_bib0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0167-4781(95)00196-4","article-title":"Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines","volume":"1305","author":"Langerak","year":"1996","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.bcp.2011.07.073_bib0055","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/bjc.1990.207","article-title":"Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R) relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody","volume":"61","author":"Dazzi","year":"1990","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.bcp.2011.07.073_bib0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2011.07.073_bib0065","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.lungcan.2006.08.012","article-title":"EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma","volume":"54","author":"Edwards","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2011.07.073_bib0070","first-page":"333","article-title":"Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers","volume":"152","author":"Pache","year":"1998","journal-title":"American Journal of Pathology"},{"key":"10.1016\/j.bcp.2011.07.073_bib0075","doi-asserted-by":"crossref","DOI":"10.1002\/jso.21901","article-title":"Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations","author":"Rena","year":"2011","journal-title":"Journal of Surgical Oncology"},{"key":"10.1016\/j.bcp.2011.07.073_bib0080","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2741\/3679","article-title":"Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer","volume":"16","author":"Giovannetti","year":"2011","journal-title":"Frontiers in Bioscience"},{"key":"10.1016\/j.bcp.2011.07.073_bib0085","first-page":"5242","article-title":"Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma","volume":"62","author":"Janne","year":"2002","journal-title":"Cancer Research"},{"key":"10.1016\/j.bcp.2011.07.073_bib0090","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2174\/156800910791054130","article-title":"Gefitinib targets EGFR dimerization and ERK1\/2 phosphorylation to inhibit pleural mesothelioma cell proliferation","volume":"10","author":"Favoni","year":"2010","journal-title":"Current Cancer Drug Targets"},{"key":"10.1016\/j.bcp.2011.07.073_bib0095","first-page":"3773","article-title":"The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index","volume":"9","author":"She","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bcp.2011.07.073_bib0100","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bcp.2011.07.073_bib0105","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bcp.2011.07.073_bib0110","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1183\/09031936.99.13352799","article-title":"Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis","volume":"13","author":"Orengo","year":"1999","journal-title":"European Respiratory Journal"},{"key":"10.1016\/j.bcp.2011.07.073_bib0115","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1074\/jbc.M807111200","article-title":"Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors","volume":"284","author":"Griffero","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2011.07.073_bib0120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/jb\/mvn175","article-title":"The eighth fibronectin type III domain of protein tyrosine phosphatase receptor J influences the formation of protein complexes and cell localization","volume":"145","author":"Iuliano","year":"2009","journal-title":"Journal of Biochemistry"},{"key":"10.1016\/j.bcp.2011.07.073_bib0125","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.bcp.2011.07.073_bib0130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/mol.107.039974","article-title":"17 beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment","volume":"73","author":"Pattarozzi","year":"2008","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.bcp.2011.07.073_bib0135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.yexcr.2005.04.024","article-title":"Stromal cell-derived factor-1alpha (SDF-1alpha\/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation","volume":"308","author":"Porcile","year":"2005","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.bcp.2011.07.073_bib0140","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1074\/jbc.271.11.6129","article-title":"Somatostatin inhibits PC Cl3 thyroid cell proliferation through the modulation of phosphotyrosine activity impairment of the somatostatinergic effects by stable expression of E1A viral oncogene","volume":"271","author":"Florio","year":"1996","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2011.07.073_bib0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0014-2999(03)01907-1","article-title":"Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines","volume":"473","author":"de Cupis","year":"2003","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.bcp.2011.07.073_bib0150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11864-008-0071-3","article-title":"Systemic treatments for mesothelioma: standard and novel","volume":"9","author":"Kindler","year":"2008","journal-title":"Current Treatment Options in Oncology"},{"key":"10.1016\/j.bcp.2011.07.073_bib0155","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1535-7163.MCT-10-0239","article-title":"Targeted therapies for non-small cell lung cancer: an evolving landscape","volume":"9","author":"Pal","year":"2010","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.bcp.2011.07.073_bib0160","first-page":"1274","article-title":"ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR\/HER2 and EGFR\/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells","volume":"9","author":"Anido","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bcp.2011.07.073_bib0165","doi-asserted-by":"crossref","first-page":"23247","DOI":"10.1074\/jbc.272.37.23247","article-title":"Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site","volume":"272","author":"Arteaga","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2011.07.073_bib0170","doi-asserted-by":"crossref","first-page":"30392","DOI":"10.1074\/jbc.M504770200","article-title":"Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis","volume":"280","author":"Clayton","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2011.07.073_bib0175","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/carcin\/21.12.2275","article-title":"Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres","volume":"21","author":"Faux","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2011.07.073_bib0180","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.bcp.2011.07.073_bib0185","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-011-0149-1","article-title":"Novel Targeted Therapies and Vaccination Strategies for Mesothelioma","author":"Bagia","year":"2011","journal-title":"Current Treatment Options in Oncology"},{"key":"10.1016\/j.bcp.2011.07.073_bib0190","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2007.09.018","article-title":"Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810)","volume":"60","author":"Kalmadi","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2011.07.073_bib0195","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.ejca.2009.02.022","article-title":"Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines","volume":"45","author":"Nutt","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.bcp.2011.07.073_bib0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2010.11.004","article-title":"Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?","author":"Agarwal","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bcp.2011.07.073_bib0205","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jtcvs.2004.11.029","article-title":"Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma","volume":"130","author":"Rascoe","year":"2005","journal-title":"Journal of Thoracic and Cardiovascular Surgery"},{"key":"10.1016\/j.bcp.2011.07.073_bib0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-4598-9-27","article-title":"Synergistic effect of gefitinib and rofecoxib in mesothelioma cells","volume":"9","author":"Stoppoloni","year":"2010","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.bcp.2011.07.073_bib0215","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/BF02573071","article-title":"Phosphatase tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of Akt phosphorylation","volume":"9","author":"Mohiuddin","year":"2002","journal-title":"Annals of Surgical Oncology"},{"key":"10.1016\/j.bcp.2011.07.073_bib0220","first-page":"2316","article-title":"Response to epidermal growth factor receptor inhibitors in non-small lung cancer cells. Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways","volume":"9","author":"Janmaar","year":"2003","journal-title":"Clinical Cancer Research"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295211005314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295211005314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:12:26Z","timestamp":1790179946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295211005314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0006295211005314"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2011.07.073","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1\/2 as antitumor targets","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2011.07.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}